UA115958C2 - Препарат, що містить глікопіролат, спосіб та пристрій - Google Patents

Препарат, що містить глікопіролат, спосіб та пристрій

Info

Publication number
UA115958C2
UA115958C2 UAA201703025A UAA201703025A UA115958C2 UA 115958 C2 UA115958 C2 UA 115958C2 UA A201703025 A UAA201703025 A UA A201703025A UA A201703025 A UAA201703025 A UA A201703025A UA 115958 C2 UA115958 C2 UA 115958C2
Authority
UA
Ukraine
Prior art keywords
glycopyrrolate
magnesium stearate
formulation
disclosed
jet
Prior art date
Application number
UAA201703025A
Other languages
English (en)
Inventor
Фергас Манфорд
Original Assignee
Вектура Лімітед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51542160&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA115958(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Вектура Лімітед filed Critical Вектура Лімітед
Publication of UA115958C2 publication Critical patent/UA115958C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Розкрито спосіб отримання фармацевтичної композиції для введення в легені, що включає спільне подрібнення на струменевому млині глікопіролату та стеарату магнію, в якому спільно подрібнений на струменевому млині глікопіролат та стеарат магнію потім піддають операції кондиціонування, яка полягає у зволоженні спільно подрібненого на струменевому млині глікопіролату та стеарату магнію. Крім того, розкрито композицію виготовлення, застосовуючи даний спосіб.
UAA201703025A 2014-09-09 2015-09-09 Препарат, що містить глікопіролат, спосіб та пристрій UA115958C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14184164 2014-09-09
PCT/EP2015/070660 WO2016038116A1 (en) 2014-09-09 2015-09-09 Formulation comprising glycopyrrolate, method and apparatus

Publications (1)

Publication Number Publication Date
UA115958C2 true UA115958C2 (uk) 2018-01-10

Family

ID=51542160

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201703025A UA115958C2 (uk) 2014-09-09 2015-09-09 Препарат, що містить глікопіролат, спосіб та пристрій

Country Status (38)

Country Link
US (2) US10532041B2 (uk)
EP (2) EP3191081B1 (uk)
JP (1) JP6502501B2 (uk)
KR (1) KR101927960B1 (uk)
CN (1) CN106604720B (uk)
AP (1) AP2017009777A0 (uk)
AR (1) AR101793A1 (uk)
AU (1) AU2015314272B2 (uk)
BR (1) BR112017003888B1 (uk)
CA (1) CA2960694C (uk)
CL (1) CL2017000560A1 (uk)
CO (1) CO2017003056A2 (uk)
CY (1) CY1124569T1 (uk)
DK (1) DK3191081T3 (uk)
DO (1) DOP2017000065A (uk)
EA (1) EA037332B1 (uk)
EC (1) ECSP17021465A (uk)
ES (1) ES2793905T3 (uk)
HR (1) HRP20201005T1 (uk)
HU (1) HUE049339T2 (uk)
IL (1) IL250427A0 (uk)
LT (1) LT3191081T (uk)
MA (2) MA40617B1 (uk)
MX (1) MX2017003080A (uk)
MY (1) MY181647A (uk)
NZ (1) NZ728435A (uk)
PH (1) PH12017500303A1 (uk)
PL (1) PL3191081T3 (uk)
PT (1) PT3191081T (uk)
RS (1) RS60299B1 (uk)
SG (1) SG11201700536XA (uk)
SI (1) SI3191081T1 (uk)
SV (1) SV2017005403A (uk)
TN (1) TN2017000077A1 (uk)
TW (1) TWI602566B (uk)
UA (1) UA115958C2 (uk)
WO (1) WO2016038116A1 (uk)
ZA (1) ZA201700658B (uk)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3595631A1 (en) * 2017-03-15 2020-01-22 Vectura Limited Method and formulation
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
WO2021143785A1 (zh) * 2020-01-15 2021-07-22 四川海思科制药有限公司 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9808470D0 (en) 1998-04-22 1998-06-17 Smithkline Beecham Plc Novel process and apparatus
GB9826284D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826286D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
JP2004515260A (ja) 2000-04-11 2004-05-27 デュラ・ファーマシューティカルズ・インコーポレイテッド 物理的に安定化された乾燥粉末製剤
WO2002008470A1 (en) 2000-07-20 2002-01-31 Campina B.V. Method for producing a crystalline tableting additive, additive thus obtained and use thereof
CA2429665C (en) 2000-11-30 2013-10-22 Vectura Limited Method of making particles for use in a pharmaceutical composition
GB0030074D0 (en) 2000-12-08 2001-01-24 Univ London Pharmacy Particulate inhalation carrier
US7309707B2 (en) 2002-03-20 2007-12-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
DE10212264A1 (de) 2002-03-20 2003-10-02 Boehringer Ingelheim Pharma Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
ITMI20022674A1 (it) 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
US20040121003A1 (en) 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US7188993B1 (en) * 2003-01-27 2007-03-13 Harold W Howe Apparatus and method for resonant-vibratory mixing
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
JO3102B1 (ar) 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0410398D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20060292077A1 (en) 2005-03-18 2006-12-28 Zhao Jonathon Z Dendritic and star-shaped contrast agents for medical devices and bioabsorbable radiopaque bulk material and method for producing same
GB0523653D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
US8074906B2 (en) 2005-07-07 2011-12-13 Nanotherapeutics, Inc. Process for milling and preparing powders and compositions produced thereby
GB0523654D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523655D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
JP5283835B2 (ja) * 2006-07-06 2013-09-04 東京エレクトロン株式会社 マイクロ波プラズマ処理装置及びマイクロ波プラズマ処理装置用ゲートバルブ
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
EP1944018A1 (en) 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Micronised particles of low-dosage strength active agents for powder formulations for inhalation
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
KR20100095437A (ko) 2007-11-07 2010-08-30 아스트라제네카 아베 아스코르브산 유도체를 포함하는 건조 분말 제제
JP2011506400A (ja) 2007-12-13 2011-03-03 ノバルティス アーゲー 有機化合物
EP2234595B1 (en) 2007-12-13 2012-11-28 Novartis AG Process for reducing the tendency of a glycopyyronium salt to aggegate during storage.
US8235314B2 (en) 2009-02-12 2012-08-07 Linde Aktiengesellschaft Nonequilibrium humidity control for jet milling
EP2417106B1 (en) 2009-04-09 2016-11-30 Novartis AG Process for preparing pyrrolidinium salts
CN102740836A (zh) 2009-04-24 2012-10-17 伊休蒂卡有限公司 用于制备商品化纳米颗粒和微粒粉末的方法
CN102858326A (zh) * 2010-04-01 2013-01-02 奇斯药制品公司 用于制备可吸入干粉所用的载体颗粒的方法
SI2560611T1 (en) 2010-04-21 2018-03-30 Chiesi Farmaceutici S.P.A. A process for preparing particles with reduced electrostatic charges
US20130157991A1 (en) 2010-08-31 2013-06-20 Osama Ahmed Aswania Dry Powder Inhalation Drug Products Exhibiting Moisture Control Properties and Methods of Administering the Same
RU2018115685A (ru) 2011-02-17 2019-03-05 Сипла Лимитед Фармацевтическая композиция
JO3510B1 (ar) * 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
RU2013155903A (ru) 2011-05-17 2015-06-27 Перл Терапьютикс, Инк. Композиции, способы и устройства для респираторной доставки двух или более активных средств
GB201205632D0 (en) 2012-03-30 2012-05-16 Vectura Ltd Method and apparatus
WO2014007766A1 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dry powder inhalers comprising a carrier other than lactose
US20150202297A1 (en) 2012-07-05 2015-07-23 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Dry powder inhalers comprising a carrier other than lactose and a ternary component
DE102012211907A1 (de) * 2012-07-09 2014-01-09 Robert Bosch Gmbh Drehschlagschrauber mit einem Schlagwerk
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
WO2014190204A1 (en) 2013-05-22 2014-11-27 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of three or more active agents
WO2015094927A1 (en) 2013-12-17 2015-06-25 Merck Sharp & Dohme Corp. Media milling process for the manufacture of active pharmaceutical ingredients in propellants

Also Published As

Publication number Publication date
ES2793905T3 (es) 2020-11-17
PL3191081T3 (pl) 2020-09-07
PH12017500303B1 (en) 2017-07-03
PH12017500303A1 (en) 2017-07-03
IL250427A0 (en) 2017-03-30
EP3689332A1 (en) 2020-08-05
RS60299B1 (sr) 2020-07-31
CN106604720B (zh) 2020-03-10
CA2960694C (en) 2021-05-04
DOP2017000065A (es) 2017-07-15
HRP20201005T1 (hr) 2020-10-16
PT3191081T (pt) 2020-05-29
JP6502501B2 (ja) 2019-04-17
MA40617B1 (fr) 2020-05-29
EP3191081A1 (en) 2017-07-19
BR112017003888B1 (pt) 2022-11-16
AR101793A1 (es) 2017-01-11
KR20170054458A (ko) 2017-05-17
TWI602566B (zh) 2017-10-21
MA50680A (fr) 2020-08-05
HUE049339T2 (hu) 2020-09-28
ZA201700658B (en) 2022-05-25
ECSP17021465A (es) 2017-05-31
MY181647A (en) 2020-12-30
TN2017000077A1 (en) 2018-07-04
DK3191081T3 (da) 2020-06-15
MX2017003080A (es) 2017-11-15
AU2015314272B2 (en) 2017-11-23
TW201617072A (zh) 2016-05-16
SI3191081T1 (sl) 2020-07-31
BR112017003888A2 (pt) 2018-01-23
US20200155506A1 (en) 2020-05-21
CL2017000560A1 (es) 2018-03-16
CO2017003056A2 (es) 2017-07-11
AP2017009777A0 (en) 2017-03-31
AU2015314272A1 (en) 2017-02-09
US20170258762A1 (en) 2017-09-14
LT3191081T (lt) 2020-07-10
EA201790544A1 (ru) 2017-09-29
EA037332B1 (ru) 2021-03-15
SG11201700536XA (en) 2017-02-27
CA2960694A1 (en) 2016-03-17
NZ728435A (en) 2017-11-24
KR101927960B1 (ko) 2018-12-11
WO2016038116A1 (en) 2016-03-17
CY1124569T1 (el) 2022-03-24
EP3191081B1 (en) 2020-03-25
SV2017005403A (es) 2017-08-23
CN106604720A (zh) 2017-04-26
JP2017527621A (ja) 2017-09-21
US10532041B2 (en) 2020-01-14
MA40617A (fr) 2017-07-19

Similar Documents

Publication Publication Date Title
EP3166981A4 (en) Oligosaccharide compositions and methods for producing thereof
EP3153169A4 (en) Method for treating tumour, pharmaceutical composition and medicine box kit
WO2016007617A3 (en) Pharmaceutical compounding kit
PH12017500239A1 (en) Abiraterone acetate formulation and methods of use
EP3208614A4 (en) Composition for diagnosing pancreatic cancer and method for diagnosing pancreatic cancer by using same
PH12017501035A1 (en) Method for the production of a pharmaceutical delivery system
MX2017003131A (es) Metodo para la preparacion de 2-alcoxi ciclohexanol.
EP3133071A4 (en) C-aryl indican derivative, and pharmaceutical composition thereof, preparation method therefor and uses thereof
EP3110446A4 (en) Methods and compositions for treating siglec-8 associated diseases
EP3438194A4 (en) PROCESS FOR PRODUCING POLYMER COMPOSITION CONTAINING CARBOXYL GROUPS
EP3175861A4 (en) Pharmaceutical composition for treating cardiovascular or cerebrovascular diseases and preparation method therefor
MA40313A (fr) Composition pharmaceutique à base d'isotrétinoïne destinée à la voie orale
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
EP3434716A4 (en) PROCESS FOR PRODUCING LATEX COMPOSITION
PH12017500303B1 (en) Formulation comprising glycopyrrolate, method and apparatus
EP3169405A4 (en) Methods, compounds, and compositions for the treatment of musculoskeletal diseases
EP3375443A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RESPIRATORY DISEASES
WO2016063289A3 (en) Pharmaceutical tablet compositions comprising rifaximin
IN2014CH00304A (uk)
EP3421032A4 (en) PARTICULARS OF A PHARMACEUTICAL COMPOSITION, ORAL DECOMPOSITION PREPARATION THEREOF AND METHOD FOR PRODUCING PARTICLES OF A PHARMACEUTICAL COMPOSITION
BR112017014842A2 (pt) composição de agente de formação de imagem, kit de agente de formação de imagem, e, método para preparação de uma composição de agente de formação de imagem
EP3159004A4 (en) Pharmaceutical composition for preventing and treating senile dementia and preparation method therefor
EP3124049A4 (en) Process for producing composition of emulsion preparation type
HUP1400082A2 (en) Deodorant composition produced by natural ingredients and process for its preparation
EP3563846A4 (en) PHARMACEUTICAL COMPOSITION AND METHOD FOR THE PRODUCTION THEREOF